Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients […]
Athersys & Mesoblast stem cells for COVID-19? Read More »
Australian stem cell biotech Mesoblast announced that it has received regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA. This is very good news for the company and an encouraging development for the field. Interestingly, last month the FDA clarified that there is expanded RMAT designation that can include gene therapies too. At the Meeting
Mesoblast gets FDA RMAT; List of 10 total designations so far Read More »
It’s a difficult, but very important road to conclusively prove that an investigational stem cell therapy is both safe and effective in order to get final approval FDA or equivalents in other countries. For this reason, it is beneficial to highlight even small, but positive steps forward including encouraging pre-clinical data. Today I’m doing a
Stem cell therapy review of good news: UC Davis, Asterias, Cynata, Mesoblast, ViaCyte Read More »
Stem cell studies continue to make big news with a mixed bag of trends including for stem cell biotech, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in
Stem cell biotech bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »
Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is expected to run from June 1 to June 10. Mesoblast will announce ““material corporate developments with respect to certain assets
Mesoblast stock on hold: Poll if you expect good or bad news Read More »
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal,
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
Allan Robins of Viacyte (pictured at left–sorry for the fuzzy image) and Paul Simmons of Mesoblast presented this morning at the CIRM Grantee Meeting. Both talks were outstanding. Robins went first. He started by saying how Viacyte had a productive pre-IND meeting with the FDA last year. I believe a target for them is to
Viacyte & Mesoblast present at CIRM Meeting Read More »
Did you predict the major events in the stem cell and regenerative medicine field this year? I tried and today’s post are the grades on my predictions. Prediction is a key part of being a scientist even if we may not think about it that much. For instance, we have to try to predict what
Grading my 20 stem cell & regenerative medicine predictions for 2024 Read More »
Intermittent fasting must be good for stem cells, right? It’s not so clear. Like many things in biology, intermittent fasting can have seemingly opposite effects. Before we get into that, the news of the week is that the FDA approved Mesoblast’s Ryoncil MSC drug for some cases of pediatric GvHD. This has sparked lively discussion.
Weekly reads: intermittent fasting and stem cells, vet warning, blastemas Read More »
Toward the end of each year I make predictions for the stem cell and regenerative medicine field for the coming year. I’ve been doing this for more than a dozen years in various forms. In this post I’m looking at the (gene-edited, stemness enriched) tea leaves for 2025 for the regenerative arena. These predictions include
25 stem cell & regenerative medicine predictions for 2025 Read More »